Appendix 4E & Annual Report to 30 June 2026
Filed with ASX · · 50 pages · English
Summary by 6ix AI
The report highlights a significant increase in revenue from ordinary activities, while the company reported a notable decrease in losses compared to the previous year. No dividends were declared during this period, and the report includes details on the company's financial position and operational activities. The report also discusses the company's ongoing clinical trials and development of its lead drug candidate, xaranetide, aimed at treating stroke patients.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Argenica Therapeutics Ltd on 6ix
Story so far
Earlier from Argenica Therapeutics
- ARG007 Shows Significant Neuroprotection in Concussion Study
- ARG007 (Xaranetide) Completes All Three FDA Requested Assays
- WHO Confirms Xaranetide as INN for ARG-007
- IND Application Advanced With Successful Completion of Assay
- Clinical Advisory Committee Established to Advance Phase 2b
Later from Argenica Therapeutics
- New Mechanism Findings Offer Insights Into Phase 2 Signal
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics